A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with ...
Satoru Osuka, M.D., Ph.D., assistant professor in the University of Alabama at Birmingham Department of Neurosurgery, has been awarded a $50,000 seed grant from the Uncle Kory Foundation to support ...
Glioblastoma is the most aggressive and most common malignant brain cancer in adults. It is currently treated with surgery, ...
studied 55 cases of recurrent anaplastic astrocytoma and glioblastoma (20 and 35, respectively); in all cases, second surgery was performed; 41 of the 55 patients (75%) underwent postoperative ...
A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 ...
Reoperation in recurrent glioblastoma patients may improve progression-free and overall survival, especially when tumors are in non-eloquent, accessible brain regions. Factors like age, gender, tumor ...
Chimerix holds the potential to have the first approval of dordaviprone for treating recurrent H3 K27M mutant high-grade ...
On-demand video webcast now available here HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc.
A systematic review of findings reported in the literature was made of current findings for the predictors of outcome in patients with recurrent glioblastoma. To search for data, using PubMed ...
Clinical research by Dana-Farber scientists suggests that combining a novel agent called navtemadlin with DNA-damaging chemotherapy for the treatment of glioblastoma, a form of brain cancer, could ...